Fred Hutch statement regarding FDA action on CTL019 immunotherapy – Fred Hutch News Service
Fred Hutch News Service |
Fred Hutch statement regarding FDA action on CTL019 immunotherapy
Fred Hutch News Service SEATTLE — AUG. 30, 2017 — Today the U.S. Food and Drug Administration approved the use of a new Novartis immunotherapy drug, CTL019, as a treatment for advanced leukemia in children and young adults. This latest FDA ruling validates the … New ‘hit-and-run’ gene editing tool temporarily rewrites genetics to treat cancer and HIVGeekWire |
|
UChicago Medicine Working to Offer Breakthrough CAR T-Cell Gene Therapy Approved Today by FDA
Newswise (press release) “CAR T-cell therapy has revolutionized the treatment of acute lymphoblastic leukemia,” according to cancer specialist John Cunningham, MD, chair of pediatrics at the University of Chicago and physician-in-chief at Comer Children’s Hospital. “I came to … |
The Scientist |
First CAR T-Cell Therapy Approved in US
The Scientist ALLINONEMOVIE, PIXABAYThe US Food and Drug Administration (FDA) announced today (August 30) that it has approved the first therapy involving chimeric antigen receptor (CAR) T cells for clinical use. Each dose of Novartis’s drug, Kymriah, will consist … |
|
UChicago Medicine working to offer breakthrough CAR T-cell gene therapy approved by FDA
EurekAlert (press release) “CAR T-cell therapy has revolutionized the treatment of acute lymphoblastic leukemia,” according to cancer specialist John Cunningham, MD, chair of pediatrics at the University of Chicago and physician-in-chief at Comer Children’s Hospital. “I came to … |
|
US clears first ‘living drug’ for tough childhood leukemia
ModernHealthcare.com The CAR–T cell treatment developed by Novartis Pharmaceuticals and the University of Pennsylvania is the first type of gene therapy to hit the U.S. market — and one in a powerful but expensive wave of custom-made “living drugs” being tested against … |